Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27398666 | 0.85 | BCL9 (0.41) | KMT2ASMN1; SMN2RECQLMAPTKDM4E | |
| SCHEMBL29020316 | 0.84 | KMT2A (0.50) | KMT2ASMN1; SMN2RECQLMAPTKDM4E | |
| SCHEMBL2287575 | 0.82 | KMT2A (0.45) | KMT2ASMN1; SMN2RECQLKDM4EMEN1 | |
| SCHEMBL2287622 | 0.81 | POLM (0.47) | KMT2ASMN1; SMN2RECQLMAPTKDM4E | |
| SCHEMBL11393056 | 0.81 | GAA (0.35) | KMT2ASMN1; SMN2RECQLMAPTKDM4E | |
| SCHEMBL29020270 | 0.80 | SMN1; SMN2 (0.40) | KMT2ASMN1; SMN2MAPTKDM4EMEN1 | |
| SCHEMBL27811600 | 0.79 | MAPT (0.38) | ACHEKMT2AMAPTKDM4EMEN1 | |
| SCHEMBL27279005 | 0.79 | L3MBTL1 (0.38) | ELANEKMT2ASMN1; SMN2RECQLMAPT | |
| SCHEMBL28230160 | 0.78 | TSHR (0.40) | KMT2ASMN1; SMN2MAPTKDM4EMEN1 | |
| SCHEMBL3812449 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109055982-A | A kind of lead bullion electrolytic smelting method | 湖南省桂阳银星有色冶炼有限公司 | 2018-12-21 | — | — | CN | claimed |
| EP-4673137-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4580638-A1 | CHEMICAL CONJUGATES, COMPOSITIONS, AND METHODS OF PREPARATION AND USE THEREOF | Transfection Holdings Limited (NZ) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024182736-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | SIONNA THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024049306-A1 | CHEMICAL CONJUGATES, COMPOSITIONS, AND METHODS OF PREPARATION AND USE THEREOF | LOPEZ GONZALEZ RICARDO (NZ) | 2024-03-07 | — | — | WO | disclosed |
| CN-116544208-A | Power overlay structure with wire bond and method of making same | 通用电气公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-115916174-A | Compositions and methods for preventing stress-induced phobia, depression-like, and anxiety-like behaviors | 纽约市哥伦比亚大学理事会 | 2023-04-04 | — | — | CN | disclosed |
| WO-2020040840-A2 | EXPANDING THE CHEMICAL SUBSTRATES FOR GENETIC CODE REPROGRAMMING | NORTHWESTERN UNIVERSITY (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020002083-A1 | SUBSTITUTED HETEROCYCLIC PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | disclosed |
| CN-102098918-A | Bioactive compounds for treatment of cancer and neurodegenerative diseases | PONIARD PHARMACEUTICALS INC | 2011-06-15 | — | — | CN | disclosed |
| EP-1914236-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | Ortho-McNeil Pharmaceutical, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-7358261-B2 | Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-6958349-B2 | Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20050159443-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | CARSON JOHN R (US) | 2005-07-21 | — | — | US | disclosed |
| EP-1495017-A2 | NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040192720-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2003087090-A2 | NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL,INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192720-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | BDKRB2, BDKRB1, MRGPRX1 | ACHE 2008/4885ELANE 511/4885KMT2A 709/4885 |
| US-20050159443-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | BDKRB2, BDKRB1, MRGPRX1 | ACHE 2008/4885ELANE 511/4885KMT2A 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.